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Abstract: Postnatal muscle growth and exercise- or injury-induced regeneration are facilitated by
myoblasts. Myoblasts respond to a variety of proteins such as cytokines that activate various
signaling cascades. Cytokines belonging to the interleukin 6 superfamily (IL-6) influence myoblasts’
proliferation but their effect on differentiation is still being researched. The Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) pathway is one of the key signaling pathways
identified to be activated by IL-6. The aim of this study was to investigate myoblast fate as well as
activation of JAK-STAT pathway at different physiologically relevant IL-6 concentrations (10 pg/mL;
100 pg/mL; 10 ng/mL) in the C2C12 mouse myoblast cell line and primary human myoblasts,
isolated from eight young healthy male volunteers. Myoblasts’ cell cycle progression, proliferation
and differentiation in vitro were assessed. Low IL-6 concentrations facilitated cell cycle transition
from the quiescence/Gap1 (G0/G1) to the synthesis (S-) phases. Low and medium IL-6 concentrations
decreased the expression of myoblast determination protein 1 (MyoD) and myogenin and increased
proliferating cell nuclear antigen (PCNA) expression. In contrast, high IL-6 concentration shifted
a larger proportion of cells to the pro-differentiation G0/G1 phase of the cell cycle, substantiated
by significant increases of both MyoD and myogenin expression and decreased PCNA expression.
Low IL-6 concentration was responsible for prolonged JAK1 activation and increased suppressor
of cytokine signaling 1 (SOCS1) protein expression. JAK-STAT inhibition abrogated IL-6-mediated
C2C12 cell proliferation. In contrast, high IL-6 initially increased JAK1 activation but resulted in
prolonged JAK2 activation and elevated SOCS3 protein expression. High IL-6 concentration decreased
interleukin-6 receptor (IL-6R) expression 24 h after treatment whilst low IL-6 concentration increased
IL-6 receptor (IL-6R) expression at the same time point. In conclusion, this study demonstrated that
IL-6 has concentration- and time-dependent effects on both C2C12 mouse myoblasts and primary
human myoblasts. Low IL-6 concentration induces proliferation whilst high IL-6 concentration induces
differentiation. These effects are mediated by specific components of the JAK/STAT/SOCS pathway.
Keywords: muscle; myogenesis; satellite cells; myoblasts; IL-6; interleukins; JAK-STAT signaling;
differentiation; proliferation; regeneration
1. Introduction
Muscle satellite cells are adult progenitor cells formed during vertebrate embryonic
development [1–3]. Adult satellite cells are quiescent cells found between the plasma membrane of
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myofibers and the basal lamina and express several marker proteins such as paired box protein 7 (Pax7),
cluster of differentiation 34 (CD34), desmin and M-cadherin [4–7]. Satellite cells are associated with
muscle growth after child-birth [8–10]. The loss of muscle fibers, due to old age and diseases, results in
blunted functional capacity as well as morbidity [11,12]. Cachexia, an extreme form of wasting of the
body, is a symptom of chronic illness and causes severe muscle loss [13]. Exercise and injury activate
Pax7+ muscle satellite cells [14–16]. The myogenic regulatory factors (MRFs) expressed by satellite
cells are required for muscle regeneration and include myoblast determination protein 1 (MyoD) [4–7].
Pax7 maintains satellite cell self-renewal [14,16–18]. MyoD expressing satellite cells exit the cell cycle
and differentiate to form multinucleated myocytes in order to repair damaged muscles [19–21]. Several
lines of evidence show that myoblasts contribute significantly to muscle regeneration in vivo [22–28].
Several myogenic cell lines derived from rodents’ muscle satellite cells have been utilized
in studying muscle progenitor cell proliferation and differentiation [29]. These cell lines include
C2C12 and L6, with C2C12 providing an excellent model to study myoblasts’ proliferation
and differentiation [30–34]. The regulation of myogenesis is controlled by transcription factors.
Early responders specific to muscle are classified as MRFs and include Myf5, MyoD, MRF4 and
myogenin [35–37]. Dimerization of MRFs with gene E2A products results in the activation of many
myogenesis-specific genes [38–42]. Expression of myogenin is a signal that myoblasts have committed
to differentiation as the process can no longer be reversed [43,44]. Another family of transcription
factors is the myocyte enhancer-binding factor 2 (MEF2) that also contributes to maturation of
differentiating myoblasts.
The mechanism(s) involved in the regulation of satellite proliferation and differentiation have
received a lot of attention although some aspects are still unclear [14,15,45]. Several growth factors
and cytokines, including leukemia inhibitory factor (LIF), transforming growth factor (TGF-β) and
hepatocyte growth factor (HGF), have been implicated as key in these processes [46–51]. Research into
the precise roles that different concentrations of these satellite cell regulators play in these processes is
still an active area of research. Previously considered an inflammatory cytokine, interleukin-6 (IL-6) is
now known to be both a cytokine produced by a variety of cell types and a myokine produced by muscle
cells [49,52–54]. Several lines of evidence from in vivo experiments have delineated the importance
of IL-6 and the activation of downstream signaling. IL-6 knockout results in reduced hypertrophic
response in rodents [48,55], suggesting a role in differentiation. However, these studies also reported
that one of the consequences of IL-6 knockout was reduced satellite cell proliferation as a result of
loss of signal transducer and activator of transcription (STAT3) signaling compared to controls [48,55].
Molecular details of the binding of IL-6 to its receptor and the resultant STAT3 phosphorylation
via the Janus kinase (JAK)-2 have been described before [56]. Trenerry and colleagues showed that
STAT3 is activated in human skeletal muscle after bouts of exercise in healthy young volunteers [57].
The activation of STAT proteins through the binding of ligands such as IL-6 is a transient process with
the effect seen within minutes to several hours [58]. IL-6 levels and satellite cell numbers increased
significantly in human muscle biopsies after an acute bout of muscle damaging physical exercise,
suggesting that IL-6 was involved in satellite cells’ proliferation [52,59]. Detailed in vitro experiments
have revealed that phosphorylated STAT3 translocates to the nucleus where it promotes transcription
of several genes [58,60]. IL-6 and phosphorylated STAT3-induced genes have been linked with cell
cycle regulation and proliferation [48]. A feedback loop exists whereby STAT3 regulates its upstream
partners such as IL-6, suppressor of cytokine signaling 3 (SOCS3) and interleukin-6 receptor [61,62].
In addition, STAT3 has been found to display context-dependent influences on several processes
including proliferation and differentiation [63,64].
The mechanism by which IL-6 influences the STAT3 signaling cascade is by binding to
the transmembrane gp130 receptor and the subsequent activation of JAK-STAT pathway [65,66].
Previous studies of IL-6 signaling showed that both the classic and trans-signaling mechanisms are
in operation [67–69]. The IL-6 receptor can exist in membrane-bound or soluble forms and both
forms bind to IL-6 with the same affinity. When IL-6 binds to the soluble IL-6 receptor (IL-6R) the
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process is referred to as trans-signaling [70,71]. The soluble IL-6R is found in body fluids [69,72].
The IL-6-IL-6R complex formed also binds to the gp130 homodimer, in a way amplifying the activities
and effect of IL-6, by inducing signaling using two mechanisms [69,72,73]. The JAK-STAT cascade
consists of JAK1, JAK2, JAK3 and Tyk2 whilst there are seven STATs, STAT1-4, STAT5a, STAT5b and
STAT6 [66,74]. The JAK-STAT cascade has been identified as important for proliferation in many cell
types including skeletal muscle in vitro [45,75] and in vivo [52,59]. Several studies have shown the
involvement of JAK-STAT cascade in myoblast proliferation in rat muscles and in in vitro cultured
primary myoblasts [49,76,77]. Whilst several studies were done on rodents, differences between rodents
and humans exists [78–80]. For in vivo experiments, there is little control of concentrations of cytokines.
Therefore, very little evidence is available on how the JAK-STAT pathway responds to different
concentrations of IL-6 under various conditions. Several studies including those by Kurosaka and
Machida have used IL-6 concentrations within the range used in this study [59,72,81,82]. Whilst the
phosphatidylinositol-3 kinase/protein kinase B (PI3K-Akt) and the p38 mitogen-activated kinase
(p38 MAPK) are known to positively regulate myogenic differentiation, the role of JAK-STAT cascade
in IL-6-mediated myoblast differentiation has not been investigated.
Therefore, the aim of this study was to evaluate the effect of physiologically relevant IL-6
concentrations on myoblasts’ proliferation, differentiation and the activation of the JAK-STAT pathway.
Proliferating myoblasts, either C2C12 or of primary human origin, were treated with different IL-6
concentrations, and cell behavior at different time points was investigated. Based on our data, the main
findings were that low IL-6 concentration induced proliferation of myoblasts as shown by increased
proliferation markers such as proliferating cell nuclear antigen (PCNA)through JAK1 activation and
feedback through SOCS1 expression. High IL-6 induced differentiation of myoblasts as shown by
increased myogenin expression through JAK2 activation and increased SOCS3 expression. Increases
in IL-6R at low IL-6 concentration were observed, possibly serving as a compensatory mechanism to
increase binding of IL-6 to its receptor to increase signaling. At high IL-6, the decrease in IL-6R observed
may serve a homeostatic role to reduce IL-6 signaling. Overall, these data imply that the concentration
of IL-6 plays a major role in determining whether activated satellite cells respond to IL-6 by proliferating
more or differentiating. Furthermore, a feedback loop exists whereby negative regulators such as
SOCS1 and SOCS3 can abrogate the effect of IL-6-mediated increase in JAK-STAT signaling.
2. Results
2.1. Effect of IL-6 on C2C12 Cell Cycling is Mediated via the JAK-STAT Signaling Cascade
The putative role of IL-6 on C2C12 immortalized muscle cell cycling was investigated using flow
cytometry. Control and IL-6-treated cells exhibited significant differences in cell cycle profiles 24 h
after treatment (Figure 1A,B). C2C12 cells treated with low (10 pg/mL) and medium (100 pg/mL) IL-6
concentrations displayed similar cell cycle profiles, albeit some small but not significant variations.
Both low and medium IL-6 concentrations resulted in decreased number of cells in quiescence/Gap1
(G0/G1) phase compared to control, with the low IL-6-treated cells increasing the proportion in synthesis
(S)-phase compared to controls (Figure 1A,B). In contrast, cells treated with high IL-6 concentration
displayed similar cell cycle profiles to controls (Figure 1A,B). Furthermore, low and medium IL-6
concentrations significantly induced PCNA protein levels compared to controls (Figure 2A, for level of
significance see Figure legends). High IL-6-treated cells had similar PCNA protein levels compared
to control cells (Figure 2A). In addition, MyoD protein levels were similar to controls for all IL-6
concentrations (Figure 2B). Immunofluorescence staining substantiated the protein results, displaying
increased PCNA levels when C2C12 cells were treated with low and medium IL-6 concentrations for
24 h (Figure 2C). Similar to MyoD, myogenin protein was not altered (Figure 2C).




Figure 1. Effect of low, medium and high IL-6 concentrations on C2C12 cell cycle progression at 
24 h. (A) Flow cytometric analysis of IL-6-treated cells to determine the effect of IL-6 
concentration on C2C12 cell cycling was done after 24 h incubation (B) C2C12 cells (%) in each 
cell cycle stage after treatment of cells with low, medium and high IL-concentrations for 24 h. 
The experiment was repeated three times. Results are presented as mean ± standard error of the 
mean (S.E.M). Statistical analysis: Analysis of variance (ANOVA) and Bonferroni post hoc test. 
*p < 0.05; relative to control. 
Figure 1. Effect of low, medium and high IL-6 concentrations on C2C12 cell cycle progression at 24 h.
(A) Flow cytometric analysis of IL-6-treated cells to determine the effect of IL-6 concentration on C2C12
cell cycling was done after 24 h incubation (B) C2C12 cells (%) in each cell cycle stage after treatment of
cells with low, medium and high IL-concentrations for 24 h. The experiment was repeated three times.
Re ults are present d as mean ± standard error of the mean (S.E.M). Statistical analysis: Analysis of
variance (ANOVA) and Bonferroni post hoc test. * p < 0.05; relative to control.




Figure 2. Effect of low, medium and high IL-6 concentrations on PCNA, MyoD and myogenin 
protein levels in C2C12 cells. (A) PCNA protein levels in C2C12 cells treated with low, medium 
and high IL-6 concentrations for 24 h. (B) MyoD protein levels in C2C12 cells treated with low, 
medium and high IL-6 concentrations for 24 h. (C) Immunofluorescence staining for PCNA and 
myogenin in C2C12 cells treated with low, medium and high IL6 concentrations for 24 h. The 
experiment was repeated three times. Immunofluorescence images were taken at 100× 
magnification. Results are presented as mean ± standard error of the mean (S.E.M). Statistical 
analysis: ANOVA and Bonferroni post hoc test. *p < 0.05. 
Addition of IL-6 for 48 h resulted in C2C12 cells responding in similar fashion to both low and 
medium IL-6 concentrations (Figure 3A,B). Low and medium IL-6 concentrations decreased the 
number of cells in the G0/G1 phases whilst increasing those in the S-phase (Figure 3A,B). Western 
blot analysis showed PCNA levels were increased when C2C12 cells were treated with low and 
medium IL-6 concentrations (Figure 4A,B). Immunofluorescence analysis substantiated these 
findings, with C2C12 cells showing increased expression of PCNA when cells were treated with low 
and medium IL-6 concentrations (Figure 4E). Whilst changes in MyoD were not statistically 
significant, treatment of cells with high IL-6 concentration resulted in increased myogenin levels 
Figure 2. Effect of low, medium and high IL-6 concentrations on PCNA, MyoD and myogenin protein
levels in C2C12 cells. (A) PCNA protein levels in C2C12 cells treated with low, medium high IL-6
concentrations for 24 h. (B) MyoD protein levels i C2C12 cells treated wi h low, medium and high
IL-6 concentrations for 24 h. (C) Immunofluorescence stai ing for PCNA and myog nin in C2C12
cells treated wit low, medium and high IL6 concentrations for 24 h. The experiment was repeated
three times. Immunofluore cence images were tak n at 100× ma nification. Results are presented as
m an ± standard error of th mean (S.E.M). Statistical analysis: ANOVA and Bonf rroni post hoc test.
* p < 0.05.
Addition of IL-6 for 48 h resulted in C2C12 cells responding in similar fashion to both low and
medium IL-6 concentrations (Figure 3A,B). Low and medium IL-6 concentrations decreased the number
of cells in the G0/G1 phases whilst increasing those in the S-phase (Figure 3A,B). Western blot analysis
showed PCNA levels were increased hen C2C12 cells were treated with low and medium IL-6
concentrations (Figure 4A,B). Immunofluorescence analysis substantiated these findings, with C2C12
cells showing increased expression of PCNA when cells were treated with low and medium IL-6
concentrations (Figure 4E). Whilst changes in MyoD were not statistically significant, treatment of cells
with high IL-6 concentration resulted in increased myogenin levels (Figure 4A,C,D). This response
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to high IL6 concentration was accompanied by no effect on PCNA levels, which remained similar to
controls (Figure 4A,B). The immunofluorescence data reinforced these findings, clearly demonstrating
that high IL-6 concentrations favor myogenic differentiation of C2C12 cells whilst low and medium
IL-6 concentrations induce C2C12 proliferation (Figure 4A,E).
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Figure 4. Concentration-dependent effect of IL-6 on C2C12 myogenic regulatory factors’ protein levels.
(A) Evaluation of PCNA, MyoD and myogenin protein levels in C2C12 cells treated with low, medium
and high IL-6 concentrations for 48 h. (B) Quantification of PCNA protein levels as shown in (A).
(C) Quantification of MyoD protei levels as sh wn in (A). (D) Quantification of myogenin protein levels
as shown in (A). (E) Immunofluoresce ce staining for PCNA and myogenin i C2C12 cells after treatment
with low, medium and high IL-6 concentrations for 48 h. The experiment was repeated three times.
Immunofluorescence images were taken at 100× magnification. Results are presented as mean ± standard
error of the mean (S.E.M). Statistical analysis: ANOVA and Bonferroni post hoc test. * p < 0.05.
To reveal mechanistic pathways through which IL-6 might affect C2C12 characteristics, the activation
of the JAK-STAT pathway in IL-6-treated cells was examined. The activation of JAK-STAT signaling
was examined in C2C12 cells via the use of antibodies against p-STAT3. All IL-6 concentrations (high,
medium and low IL-6 levels) resulted in early induction of STAT3 phosphorylation, shown 5 min
after addition of IL-6 (Figure 5A,B). Only high IL-6 concentration (10 ng/mL) appeared to prolong
phosphorylation of STAT3 up to 10 min but no longer between 15 and 30 min (Figure 5A,B). Since
treatment of C2C12 cells with low and medium IL-6 concentrations exhibited similar effect on cell cycle
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and associated proteins, low IL-6 concentration (10 pg/mL) and high IL-6 concentration (10 ng/mL) were
chosen for further comparative experiments. To verify that effects of IL-6 are indeed mediated by STAT3
phosphorylation, responses were assessed in the presence of a JAK2-STAT3 inhibitor, AG490. AG490 was
added to cultured C2C12 cells in the 48 h experiment with every media change (Figure 5C,D). Similar
stocks of C2C12 cells were used for both inhibitor and no inhibitor experiments. Addition of STAT3
inhibitor resulted in reduced STAT3 phosphorylation compared to controls, irrespective of the IL-6
concentration used at the beginning of the 48 h experiment (Figure 5C). Finally, addition of the inhibitor
resulted in decreased PCNA, MyoD and myogenin levels in IL-6-treated cells compared to controls
at the end of the 48 h experiment (Figure 5D,E). At the end of the 48 h incubation, the JAK2-STAT3
inhibitor, AG490, resulted in more cells being in the G0/G1phase with a consequential decrease in cells
in the S-phase for both low and high IL-6 concentrations (Figure 6A,B). The STAT3 inhibitor completely
inhibited cell division in both low and high IL-6 concentration-treated experiments (Figure 6A,B).
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Figure 5. IL-6 activates the STAT3 signaling pathway in C2C12 cells. (A) Evaluation of p-STAT3
protein levels in C2C12 cells at 5 min up to 30 min after treatment of cells with ow, medium and high
IL-6 concentrations. (B) Quantification of western blot images shown in (A). (C) Effect of JAK-STAT
inhibitor, AG490, on p-STAT3 expression in C2C12 cells over 15 min after treatment with low and
high IL-6 concentration. (D) Effect of JAK-STAT inhibitor, AG490, on PCNA, MyoD and myogenin
protein levels in C2C12 cells after treatment with low and high IL-6 concentrations (top panel) and
densitometric quantification of images (lower panel) (E) Quantification of PCNA, MyoD and myogenin
protein levels in C2C12 cells after treatment with low and high IL-6 concentrations plus JAK-STAT
inhibitor, AG490. The experiment was repeated three times. Immunofluorescence images were taken
at 100× magnification. Results are presented as ean ± standard error of the mean (S.E.M). Statistical
analysis: ANOVA and Bonferroni post hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 6. Effect of IL-6 concentration and JAK-STAT inhibitor on C2C12 cell cycling at 48 h. (A) Flow
cytometric analysis of IL6-treated cells, with or without JAK-STAT inhibitor, to determine the effect of
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error of the mean (S.E.M). Statistical analysis: ANOVA and Bonferroni post hoc test.
2.2. Primary Human Myoblasts (PHM) Characterisation
The C2C12 mouse myoblast cell line is one of the most used muscle-derived progenitor cell lines
for in vitro experimentation [80]. C2C12 cells have enhanced and rapid proliferation capacity and
differentiate into myofibers effectively [80]. Isolated primary myoblasts have a higher sarcomere
assembly than C2C12 under both proliferation and differentiation conditions [79]. This suggests that
primary myoblasts represent the characteristics of the skeletal muscle more accurately than C2C12
cells/myotubes [78]. In order to fully elucidate the effect of IL-6 on human myogenesis and the signaling
cascades involved, we therefore used primary human myoblasts in further investigations.
Primary human myoblasts (PHMs) were isolated using the micro-explant technique. Preliminary
characterization of isolated primary human myoblast cells was done through immunofluorescence
staining for Pax7 and desmin (Figure 7A–F). The myogenic differentiation potential of the isolated
cells was evaluated by exposure to differentiation inducing conditions for 7 days and immunostaining
performed for desmin and myogenin. PHM expressed Pax7 and desmin and as expected phenotypic
characterization of PHM showed that expression of Pax7 was in ≥ 90% of the cell population
(Figure 7A–E). Furthermore, multinucleated fibers appeared after 7 days of incubation in differentiation
media (Figure 7F). PHMs stained positively for the terminal differentiation transcription factor
myogenin and the sarcomere specific protein desmin after incubation under differentiation inducing
conditions (Figure 7F). The data show that isolated PHMs were able to preserve muscle phenotype
even after long periods of sub-culturing. A comparison of C2C12 cells versus PHMs showed distinct
differences in cell cycle profiles, justifying the choice of using primary human myoblasts over C2C12
cells to study human myogenesis (Figure 7G). PHMs showed increased number of cells in G0/G1
phase prior to IL-6 treatment and decreased number of cells in S phase compared to C2C12 cells
(Figure 7G). This is however expected as primary cells are known to have reduced proliferative
capabilities compared to immortalized cells.
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Figure 7. The phenotypic characterization of primary human myoblasts. (A–D) Flow cytometric
analysis of Primary Human myoblasts (PHMs) was performed as described in Materials and Methods
section. Average of cells (%) staining positive for Pax7 and desmin are shown. (E) Several preparations
of the PHMs were analyzed and sho n is representative of eight donors. Results are shown as
mean ± S.D. (F) Red outlined column (first column): Preliminary characterization of isolated cells as
performed o ascertain whether the culture generated contained myoblasts: Pax7 (gre n), desmin (red)
(fluorescent microscopy at 100× magnification). Gre outlined Column (second column): PHMs were
exposed to differentiation inducing conditions for 7 days and stained via immunofluorescence for
desmin (red), myogenin (green) and nuclei (blue). White arrows indicate multinucleated myofibres.
Blue outlined Column (third column): PHMs were able to preserve their differentiation ability after long
periods of sub-culturing. Cells were maintained and passaged for two months (imaged by confocal
microscopy (myogenin) at 400× magnification or fluorescent microscopy (Trans) at 200× magnification).
(G) Comparison of C2C12 and PHMs. Cells were analyzed through flow cytometry and percentages of
cells in each cell cycle stage quantified. * p < 0.05; ** p < 0.01; *** p < 0.001.
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2.3. High IL-6 Concentration Induced Myogenic Differentiation in Primary Human Myoblasts (PHMs)
To evaluate IL-6-mediated changes in PHMs, cells were treated with low and high IL-6
concentrations for 24 and 48 h followed by determination of PCNA and myogenic regulatory factors
(MRFs), MyoD and myogenin. Western blot analysis shows that at 24 h low IL-6 concentration caused
significant increases in PCNA levels compared to controls (Figure 8A,C). At the same time point,
low IL-6 had essentially no effect on MyoD expression compared to controls (Figure 8A,C). In contrast,
treatment of PHMs with high IL-6 concentration resulted in increased MyoD levels compared to
control cells at the 24 h time point (Figure 8A,C). Immunofluorescence analysis largely substantiated
these findings (Figure 8E). After 24 h of incubation, low IL-6 concentration caused increased PCNA
expression (Figure 8E). High IL-6 concentration-treated cells displayed MyoD and myogenin levels
similar to controls, whilst PCNA was decreased.
Western blot analysis showed that further incubation of cells with high IL-6 concentration up to 48 h
resulted in significant decrease in PCNA levels (Figure 8B,D). High IL-6 concentration caused significant
increase in both MyoD and myogenin levels at 48 h (Figure 8B,D). These results are different from
those obtained at 24 h. Thus IL-6 display time-dependent effects in PHMs. More importantly, increase
in myogenin expression is a late event (48 h) after IL-6 exposure whilst increase in MyoD expression
occurs early (24 h). The increased expression of MyoD early on before differentiation is in agreement
with the myoblast phenotype and the order of events during myogenesis. Myogenic regulatory
factors were clearly affected more in PHMs than in C2C12 cells, especially MyoD. Immunofluorescence
data substantiated the western blot analysis, with the high IL-6 concentration markedly increasing
the levels of MyoD and myogenin at the 48 h time point (Figure 8E). Thus, high IL-6 concentration
favors differentiation over proliferation. Terminal differentiation of myoblasts, as shown by increased
myogenin expression, induced by high IL-6 concentration occurred concomitantly with a decrease in
PCNA expression.
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Figure 8. Concentration- and time-dependent effects of low and high IL-6 concentrations on PCNA,
MyoD and myogenin expression in PHMs. (A) Western blot determination of PCNA, MyoD and
myogenin protein levels 24 h after treatment with low and high IL-6 concentrations. (B) Western
blot determination of PCNA, MyoD and myogenin protein levels 48 h after treatment with low
and high IL-6 concentrations. (C) Quantification of PCNA, MyoD and myogenin protein levels as
shown in (A). (D) Quantification of PCNA, MyoD and myogenin protein levels as shown in (B).
(E) Immunofluorescenc staining for PCNA, MyoD and enin protei in PHMs after treatment
with low and high IL-6 for 24 and 48 h. The experiment was repeated three times. Immunofluorescence
images were taken at 100× magnification. Results are presented as mean ± standard error of the mean
(S.E.M). Statistical analysis: ANOVA and Bonferroni post hoc test. * p < 0.05; *** p < 0.001.
2.4. IL-6 Concentration-Dependent Activation of JAK2-STAT3 Signaling in Human Myogenesis
Given the comprehensive analysis of cell cycle and myogenic regulatory factors in C2C12 cells,
further inve tigation using PHMs focused on the role play d by JAK-STAT signaling in IL-6-mediated
behavior of primary hum n myoblasts. PHMs were trea ed with low and high concentrations of IL-6
and evaluation of the signaling pathways activated was done. In PHMs, activation of the JAK-STAT
signaling pathway was followed up to 8 h after addition of IL-6, through evaluation of p-JAK1, p-JAK2
and p-STAT3 levels. Time points included 10, 15, 30, 60 min and 8 h. Figure 9 presents results on some
time points as well as the effects of IL-6 concentrations. Without IL-6, there were no changes in p-JAK1
or p-JAK2 at any t me points.
Addition of IL-6 activated both JAK1 and JAK2 i a concentration -de endent fashion
(Figure 9A–D). Low IL-6 concentration resulted in significantly increased phosphorylation of JAK1
(Figure 9A,C). An initial increase in p-JAK1 due to high IL-6 concentration soon dissipated (Figure 9A,C).
In contrast, low IL-6 concentration was able to maintain increased p-JAK1 levels over a longer time,
up to one hour (Figure 9A,C). Treatment of primary human myoblasts with low IL-6 concentration
resulted in sig ificant d crease in p-JAK2 compared to controls (Figure 9B,D). In contras to low IL-6
concentration, high IL-6 concentration resulted in significant increase in p-JAK2 and this increase was
maintained over 8 h (Figure 9B,D). Immunofluorescence analysis substantiated western blot analysis,
albeit with minor visual differences (Figure 9E). These minor differences might be borne out of the fact
that confocal microscopy is qualitative whilst western blot analysis shows quantitative differences. In
summary, low IL-6 concentration activated the phosphorylation of JAK1 whilst high IL-6 concentration
activated the phosphorylation of JAK2.
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Figure 9. Effect of low and high IL-6 concentrations on JAK1 and JAK2 phosphorylation in PHMs. (A)
Effect of low and high IL-6 concentration on JAK1 phosphorylation over 8 h. (B) Effect of low and high
IL-6 concentration on JAK2 phosphorylation over 8 h. (C) Quantification of p-JAK1 as shown in (A). (D)
Quantification of p-JAK2 as shown in (B). (E) Immunofluorescence staining for p-JAK1 after treatment of
PHMs with low and high IL-6 concentration over 8 h. (F) Immunofluorescence staining for p-JAK2 after
treatment of PHMs with low and high IL-6 concentration over 8 h. (G) Immunofluorescence staining
for p-STAT3 after treatment of PHMs with low and high IL-6 concentration over 8 h (H) Quantification
of p-STAT3 levels as shown in (G). The experiment was repeated three times. All immunofluorescence
images were taken at 100× magnification. Results are presented as mean ± standard error of the mean
(S.E.M). Statistical analysis: ANOVA and Bonferroni post hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001.
JAKs are known to phosphorylate STATs. This concentration-dependent activation of the JAKs
may have affected STATs phosphorylation. Treatment of PHMs with low IL-6 concentration did
not affect p-STAT3 levels with levels predominantly similar to or lower than controls up to 60 min
(Figure 9G,H). At 8 h the levels of p-STAT3 had increased significantly. High IL-6 concentration
however, caused significant increase in p-STAT3 levels at early time points up to 30 min of incubation
and after 60 min of incubation remained significantly higher (Figure 9G,H).
We hypothesized that regulators of the JAK-STAT pathway are likely to come into play at later
stages of the IL-6-mediated changes in cell behavior. We therefore evaluated the levels of SOCS1 and
SOCS3 after addition of IL-6 for 24 and 48 h. After 24 h of incubation, the data show that low IL-6
concentration resulted in significantly decreased SOCS3 levels but increased SOCS1 levels compared
to both controls and high IL-6 concentration (Figure 10A,C). High IL-6-treated cells displayed similar
levels of both SOCS1 and SOCS3 compared to controls (Figure 10 A,C). After 48 h incubation, low IL-6
concentration showed elevated SOCS1 levels whilst high IL-6 concentration resulted in elevated SOCS3
levels (Figure 10B,D). Immunofluorescence analysis confirmed these results with minor differences
(Figure 10E). Considering data on IL-6 effects on myogenic regulatory factors acquired from C2C12
cells and presented earlier, these data in PHMs suggest that elevated levels of SOCS3 are associated
with cell differentiation. Overall, the data demonstrate that IL-6 activates the JAK-STAT signaling
pathway and this can induce myoblast proliferation or differentiation depending on the JAK-STAT
components involved and that IL-6 induces regulatory feedback.
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Figure 10. Concentration- and time-dependent effects of low and high IL-6 concentrations on 
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The transmembrane complex of IL-6 and its receptor IL-6R, allows IL-6 to bind to gp130 
subunits of the receptor. Given the relatively long exposure of the PHMs to IL-6 in the media, an 
investigation was done on the effect of IL-6 on expression of IL-6 receptor in human primary cells. 
Indeed, IL-6R protein levels were altered by exposure to IL-6 (Figure 11). These alterations 
exhibited both positive feedback and downregulation at different times and with different 
concentrations of IL-6. At the 24 h time point western blot data show that low IL-6 concentration 
resulted in an upregulation of its receptor, IL-6R (Figure 11A,C). On the contrary, high IL-6 
concentration resulted in no change in IL-6R (Figure 11A,C). After 48 h of incubation with IL-6, IL-6R 
levels were downregulated by treatment with both low and high IL-6 concentrations (Figure 11B,C). 
Thus, the upregulation of IL-6R protein was not sustained after 48 h at which time both 
concentrations had protein levels significantly below basal levels, probably indicating negative 
feedback (Figure 11A–C). RT PCR analysis of IL-6R transcripts also confirmed the results 
obtained via western blot indicating that this was an influence at the level of transcription 
factors (Figure 11D). Immunofluorescence data mirrored the protein data obtained (Figure 
11E). 
 
Figure 10. Concentration- and time-dependent effects of low and high IL-6 concentrations on SOCS1
and SOCS3 protein levels in PHMs. (A) Western blot determination of SOCS3 and SOCS1 protein
levels 24 h after treatment with low and high IL-6 concentrations. (B) Western blot determination
of SOCS3 and SOCS1 protein levels 48 h after treatment wi h low and high IL-6 concentrations.
(C) Quantification of SOCS3 and SOCS1 protein levels as shown in (A). (D) Quantification of SOCS3
and SOCS1 protein levels as shown in (B). (E) Immunofluorescence staining for SOCS3 and SOCS1
after treatment of PHMs with low and high IL-6 concentration for 48 h. The experiment was repeated
three times. Immunofluorescence images were taken at 100× magnification. Results are presented as
mean ± standard error of the mean (S.E.M). Statistical analysis: ANOVA and Bonferroni post hoc test.
* p < 0.05; ** p < 0.01.
2.5. IL-6 Receptor Regulation in Response to IL-6 Treatment
The transmembrane complex of IL-6 and its receptor IL-6R, allows IL-6 to bind to gp130 subunits
of the receptor. Given the relatively long exposure of the PHMs to IL-6 in the media, an investigation
was done on the effect of IL-6 on expression of IL-6 receptor in human primary cells. Indeed, IL-6R
protein levels were altered by exposure to IL-6 (Figure 11). These alterations exhibited both positive
feedback and dow regulation at diffe nt imes and with different concentrations of IL-6. At the
24 h time point west rn blot data show that low IL-6 concentration resulted in an upregulation of its
receptor, IL-6R (Figure 11A,C). On the contrary, high IL-6 concentration resulted in no change in IL-6R
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(Figure 11A,C). After 48 h of incubation with IL-6, IL-6R levels were downregulated by treatment with
both low and high IL-6 concentrations (Figure 11B,C). Thus, the upregulation of IL-6R protein was not
sustained after 48 h at which time both concentrations had protein levels significantly below basal
levels, probably indicating negative feedback (Figure 11A–C). RT PCR analysis of IL-6R transcripts
also confirmed the results obtained via western blot indicating that this was an influence at the level
of transcription factors (Figure 11D). Immunofluorescence data mirrored the protein data obtained
(Figure 11E).




Figure 11. Concentration- and time-dependent effects of low and high IL-6 concentrations on 
IL-6R expression in PHMs. (A) Western blot determination of IL-6R protein levels 24 h after 
treatment with low and high IL-6 concentrations. (B) Western blot determination of IL-6R protein 
levels 48 h after treatment with low and high IL-6 concentrations. (C) Quantification of IL-6R protein 
levels as shown in (A). (D) Quantification of IL-6R mRNA levels after treatment of cells with low and 
high IL-6. (E) Real time PCR analysis of IL-6R mRNA transcripts 24 h after treatment of PHMs with 
low and high IL-6 concentration. (F) Real time PCR analysis of IL-6R mRNA transcripts 48 h after 
treatment of PHMs with low and high IL-6 concentration. (E) Immunofluorescence staining for 
IL-6R after treatment of PHMs with low and high IL-6 concentration for 24 (top panel) and 48 h 
(lower panel). The experiment was repeated three times. Immunofluorescence images were 
taken at 100× magnification. Results are presented as mean ± standard error of the mean (S.E.M). 
Statistical analysis: ANOVA and Bonferroni post hoc test. *p < 0.05; **p < 0.01. 
3. Discussion 
The main findings of this study were that IL-6 has concentration- and time-dependent effects on 
both C2C12 and primary human myoblasts, with evidence that low IL-6 concentration induces 
proliferation whilst high IL-6 concentration induces differentiation. Taking combinations of results 
Figure 11. Concentration- and time-dependent effects of low and high IL-6 concentrations on IL-6R
expression in PHMs. (A) Western blot determination of IL-6R protein levels 24 h after treatment with
low and high IL-6 c nce trations. (B) W stern blot determination of IL-6R protein levels 48 h after
treatment wit low and high IL-6 conce trations. (C) Quantification of IL-6R protein levels as shown in
(A). (D) Qu ntification of IL-6R mRNA levels after treatment of cells with low and high IL-6. (E) Real
time PCR analysis of IL-6R mRNA transcripts 24 h after treatment of PHMs with low and high IL-6
concentration. (E) Real time PCR analysis of IL-6R mRNA transcripts 48 h after treatment of PHMs
with low and high IL-6 concentration. (E) Immunofluorescence staining for IL-6R after treatment of
PHMs with low and high IL-6 concentration for 24 (top panel) and 48 h (lower panel). The experiment
was repeated three times. Immunofluorescence images were taken at 100× magnification. Results are
presented as mean ± standard error of the mean (S.E.M). Statistical analysis: ANOVA and Bonferroni
post hoc test. * p < 0.05; ** p < 0.01.
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3. Discussion
The main findings of this study were that IL-6 has concentration- and time-dependent effects
on both C2C12 and primary human myoblasts, with evidence that low IL-6 concentration induces
proliferation whilst high IL-6 concentration induces differentiation. Taking combinations of results
together, this study shows firstly that low and medium IL-6 concentrations promoted both C2C12
and PHMs proliferation via upregulation of PCNA protein levels and decreased levels of myogenic
regulatory factors, MyoD and myogenin. Low and medium IL-6 concentrations also activated the
JAK1-STAT3 cascade to promote myoblasts’ proliferation. In contrast, high IL-6 concentration decreased
PCNA protein levels and promoted myoblasts’ differentiation through increasing the levels of myogenic
regulatory factors, MyoD and myogenin. Also, in contrast, high IL-6 concentration activated the
JAK2-STAT3 cascade. Secondly, inhibition of the JAK-STAT3 cascade in the C2C12 cells confirmed
and illuminated several findings such as myoblasts’ reduced proliferation in the presence of AG490,
a JAK-STAT3 inhibitor, a finding also associated with reduced expression of PCNA, despite the presence
of low IL-6. Downregulation of PCNA means that PCNA is a STAT3 target gene. In contrast, despite the
presence of high IL-6, inhibition of the JAK2-STAT3 cascade was shown to prevent early differentiation
of myoblasts, through the repression of genes associated with myogenic differentiation (MyoD and
myogenin). Thus, STAT3 plays a central role in controlling myoblast proliferation and differentiation.
Thirdly, another significant observation was the IL-6-mediated increase in the expression of JAK-STAT3
downstream genes such as SOCS1 and SOCS3 and IL-6R. Specifically, JAK1-STAT3 was associated with
increased SOCS1 expression, whilst JAK2-STAT3 was associated with increased SOCS3 expression.
Low and high IL-6 concentrations affected IL-6R differently, with low IL-6 concentration increasing
IL-6R protein levels whilst high IL-6 concentration reduced IL6-R levels (findings are summarized in
Figure 12). These findings provided insights into mechanisms controlling myoblast fate in skeletal
muscle. Finally, the time-dependent effects were seen specifically for PCNA and myogenin. Specifically,
the effect of high IL-6 on PCNA reduction and myogenin increases took 48 h to occur, whereas with
low IL-6 the increase in PCNA was rapid and evident at 24 h. Below we discuss our results in the
context of effects of IL-6 on different cell types and under different conditions as determined by
others. The discussion then focuses on the implications of our data on skeletal muscle physiology and
pathological conditions.
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Muscle injury and debilitating skeletal muscle diseases cause muscle satellite cells to undergo
a process of activation, proliferation and finally differentiation. Several cytokines are thought to
be involved in the activation of satellite cells including LIF [28,49,83]. LIF is a member of the IL-6
superfamily. Early differentiation is blocked until the pro-proliferation signals are reduced or eclipsed
by pro-differentiation signals. The order of events as displayed by our data during IL-6-mediated
differentiation of primary human myoblasts is in line with published data. It is known that MyoD is
expressed early on before differentiation [35,38,41,45,74,84–86]. The expression of myogenin finally
shows when myoblasts are fully committed to differentiation and is therefore a late event. Only high
IL-6 induced myogenin in the current study. Once cells are differentiating, proliferation is reduced and
here, the data clearly demonstrate decreases in PCNA levels once myoblasts start expressing myogenin,
a terminal differentiation marker.
Several signaling pathways have been associated with the process of myogenesis and these include
the MEK-ERK, PI3K-Akt, Notch and the JAK-STAT pathways [74,85,87,88]. In this study, specific focus
was on the JAK-STAT signaling pathway, since previous work showing that the JAK-STAT pathway
predominates over other pathways in terms of mediating IL-6 effects [72,89,90]. However, how this
signaling pathway is activated by IL-6 during different phases of myogenesis has not been fully
elucidated. Also, other studies did not consider concentration or duration of exposure of cells to IL-6
and the study by Hassan for example was in hepatic disorders [89]. In agreement with published data,
our work reveals that JAK1-induced signaling operates mainly in the proliferation stage of muscle
regeneration [87,91]. The interaction between different members of the JAK-STAT pathway results in
context-dependent regulation of cellular processes [74,92–94]. In our study we show the involvement
of JAK1/2, STAT3 and SOCS1/SOCS3 in myoblasts proliferation and differentiation. Several murine
studies and studies involving macrophages showed that STAT3 can direct myoblasts’ behavior in
a context-dependent fashion, with the involvement of specific JAKs [45,74,92,95]. A study by Sun and
colleagues concluded that there are several JAK-STAT cascades that are activated in myoblasts and
these might have different effects on proliferation and differentiation [87]. STAT3 ablation has been
shown to result in p-STAT3, MyoD1 and myogenin downregulation before and our data confirmed this
result in a context with somewhat more physiologically relevant IL-6 interventions [96]. Future studies
focusing on delineating how phosphorylated STAT3 can activate different genes in response to different
IL-6 concentrations must be undertaken.
Several studies have evaluated the effect of IL-6 on a variety of cells in vitro. Kurosaka and Machida
evaluated the effects of IL-6 on rat primary muscle satellite cell proliferation [97]. The authors used
IL-6 concentrations similar to the ones used in the current study. The authors used IL-6 concentrations
ranging from 10 pg/mL up 100 ng/mL and they showed that 10 pg/ ml–1 ng/mL IL-6 induced satellite
cell proliferation [97]. These results are similar to our data showing that low (10 pg/mL) and medium
(100 pg /mL) IL-6 concentrations induced PCNA protein levels. Our data showing high (10 ng/mL)
IL-6 concentration increased p-STAT3 activation resulting in primary myoblast differentiation, agree
with data obtained by the same authors. Results from Kurosaka and Machida show that even 1 ng/mL
IL-6 increased p-STAT3 activation [97]. However, Kurosaka and Machida showed that IL-6 induced
satellite cell proliferation via the JAK2-STAT3 pathway. Our data showed that it is the JAK1-STAT3
pathway that is induced in primary myoblasts by low IL-6 concentration. Although in our study we
did not use 1 ng/mL IL-6, our observations that medium (100 pg/mL) and low (10 pg/mL) IL-6 promote
myoblasts proliferation, appear to agree with results obtained by Kurosaka and Machida when they
used 1 ng/mL IL-6. One of our main aims was to try to cover a wide range of IL-6 concentrations, because
several studies performed in animals and humans on the role of IL-6 in myogenesis, exercise-induced
hypertrophy and aging, have delivered contrasting results [55,59,98,99]. Therefore, our study adds to
our understanding of the human myogenesis process and how it is influenced by IL-6.
The JAK-STAT signaling pathway has several classes of regulators. These include the suppressors
of cytokine signaling (SOCS) and the protein tyrosine phosphatases (PTPs) [74,91]. Several members
of the SOCS family are known to be involved in myoblast behavior [74,100]. Specifically, SOCS1 and
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SOCS3 have been implicated in myoblasts proliferation and differentiation [91]. In the aforementioned
study, Diao and colleagues showed that both SOCS1 and SOCS3 promote myogenic differentiation of
mouse myoblasts in response to LIF [91]. However, our study demonstrates the involvement of SOCS1
and SOCS3 in primary human myoblasts proliferation and differentiation, respectively. Despite being
members of the same superfamily, LIF and IL-6 may operate differently. In addition, it is important to
note that our study involves the use of primary human myoblasts whilst the above study used mouse
myoblasts. Other contrasting data having been published with some studies showing that SOCS3 is
involved in cell differentiation as we show in this study [101] and others showing that SOCS3 is actually
involved cell proliferation [97,100,102]. These contrasting findings may be due to concentrations or
exposure time of the factors influencing SOCS3. Indeed, only treatment of primary human myoblasts
in the current study with high IL-6 concentration resulted in significant increase in SOCS3 expression.
When using IL-6 concentrations comparable to those used in the current study, Senn and colleagues
demonstrated that IL-6 can induce SOCS3 expression in hepatocytes [103].
In the context of skeletal muscle, an increase in IL-6R mRNA has been seen in regenerating
myotubes [82,104] which shows a possible role amongst the many factors regulating myoblast
proliferation or differentiation. Wada and colleagues showed that anti-IL-6R antibody can be used to
promote skeletal muscle regeneration in mice [82]. That study showed that low IL-6 concentration
caused increased IL-6R protein levels. In contrast, high IL-6 concentration in the current study resulted
in greater activation of JAK2-STAT3 and could be accountable for the down-regulation of the IL-6R at
24 and 48 h. Extended signaling through the IL-6R in IL-6-treated cells could trigger an auto-regulation
feedback response. Alteration in receptor regulation between low and high IL-6 concentration could be
responsible for their seemingly alternate roles in proliferation and differentiation. These speculations
require further experiments on the physical interactions between the IL-6R and the JAKs to confirm
these possible explanations. Physiological conditions of sustained high IL-6 in circulation in humans
include cachexia [105–108]. Therefore, the data presented here could provide valuable information on
possible treatment avenues for conditions affecting muscle, such as cachexia or myopathy. Low IL-6
concentration may induce IL-6R expression to promote sensitivity to the cytokine, whilst high IL-6
concentration reduces IL-6R expression to protect against too high IL-6 signaling. It is known that
a soluble form of the IL-6 receptor is also secreted and IL-6 may signal via both the soluble and the
membrane-associated form of IL-6R [45,74,92]. The possible involvement of this soluble receptor
requires further investigations that are beyond the scope of this study. Produced as a result of
alternative splicing and limited proteolytic processing, the soluble IL-6R is found in several body
fluids [69,72]. The complex formed as a result of the coming together of IL-6 and the soluble IL-6R bind
to gp130 homodimer on cells lacking the IL-6 receptor and has been suggested to amplify the activities
and effect of IL-6 [69,72,73]. It is plausible therefore to postulate that the effects of IL-6 observed in
this study might have involved the soluble IL-6R. Specifically, when the IL-6 concentration to which
cells were exposed was high, both receptors may have been involved in promoting differentiation.
IL-6R dynamics are also more complex than the comparison of IL-6 binding to surface-based and
soluble receptors. For example, turnover of both receptors occurs under normal conditions and IL-6
bound to surface receptors may not remain on the surface but internalize. Studies to elucidate this
phenomenon should be done in future in the context of dose and response time.
Whilst the C2C12 cell line is useful to study muscle biology and processes such as myogenesis
and metabolism, the cell line has several limitations. Firstly, higher passage number cells have reduced
proliferative and differentiation capabilities. Also, C2C12 cells lack the cell cycle regulator, p16 [80].
The effect of low IL-6 concentration on PCNA in C2C12 cells was still large at 48 h, suggesting that the
immortalized cell line had a greater propensity to remain in proliferation mode. Our study confirmed
that primary myoblasts proliferate slower than immortalized cells and differentiation was slightly
delayed in primary myoblasts compared to C2C12 cells. However, high IL-6 concentration increased
myogenin expression at 48 h much more prominently in C2C12 cells. All these responses were inhibited
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with addition of the JAK-STAT3 phosphorylation inhibitor, AG490, confirming that the effects were
indeed due to IL-6.
Thus, our study demonstrates, for the first time in primary human myoblasts, that the level of
IL-6 and the consequential activation of the JAK-STAT pathway can determine the proliferation or
differentiation of human myoblasts in vitro, making IL-6 in the muscle microenvironment a critical
cytokine in the context of regeneration. The critical balance between proliferation and differentiation
of myoblasts is important. Here we show that the duration of exposure to IL-6 plays an important
role. Importantly, the data suggests that IL-6 can modulate myoblast behavior in a paracrine manner,
as exogenous addition of IL-6 induced several changes to the myoblasts. Our study has confirmed
previous results and extended the knowledge of the role of IL-6 concentration on muscle regeneration.
Mechanistic data presented here provide new directions in understanding the effect of cytokines on
myoblasts proliferation and differentiation.
4. Materials and Methods
4.1. IL-6 Treatment Protocol
Cultured C2C12 cells and primary human myoblasts were treated with a range of IL-6 (PeproTech,
Rehovot, Israel) concentrations ((low (10 pg/mL), medium (100 pg/mL) and high (10 ng/mL)) and
a control group supplemented with PBS. In a bid to cover a wide range of IL-6 concentration and not to
repeat what has been researched on, we chose the above IL-6 concentrations. Several studies, including
Kurosaka and Machida [81,97] have used IL-6 within the same range. Standard media was removed
from the wells and then standard media containing the above concentrations of IL-6, were added to
cultured cells. This media change was regarded as time 0 h. Incubation was continued for 24 h after
which cells were harvested for assays as described below. This was taken as time 24 h. For longer
incubations, media was removed at 24 h and fresh IL-6 supplemented media was added to cultured
cells for the next 24 h until the end of experiment (48 h). The replacement of the media with fresh media
(2 mL per well in a 6-well plate) supplemented with IL-6 was done to maintain the concentration of
IL-6 within the media. After the specified incubation periods, cells were harvested and used in assays
as described below. All chemicals used in the study were supplied by Sigma-Aldrich (Aston Manor,
South Africa) unless otherwise stated.
4.2. Cell Culture
C2C12 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, D5546) supplemented
with 10% (v/v) Fetal Bovine Serum (FBS, GIBCO™, Paisley, Scotland) 1% (v/v) Penicillin/Streptomycin
(PenStrep, P4333) and 6.8% (v/v) L-Glutamine (200 mM, G7513). The cells were kept at 37 ◦C in
a humidified incubator with 5% CO2. Primary human myoblasts were cultured in a medium made
up of Ham’s F10 Nutrient Mixture Medium (F10, N6013) supplemented with 20% (v/v) Fetal Bovine
Serum (FBS, GIBCO™, Paisley, Scotland), 2% (v/v) Penicillin/Streptomycin (PenStrep, P4333), 0.1%
(v/v) Gentamicin (GIBCO™, Paisley, Scotland, 50 mg/mL, 15750-060), 6.8% (v/v) L-Glutamine (200 mM,
G7513) and 10 ng/mL rhFGF (Promega, Madison, WI, USA, G5071). Cells were passaged with
Trypsin-EDTA once 70%–80% confluence was reached.
4.3. Isolation and Culture of Human Primary Myoblasts
The isolation and culture of human primary myoblasts was done based on published protocols
with minor modifications [109–111]. Eight healthy male subjects were recruited who participated
in light exercises not more than twice per week and were not on chronic medication. All subjects
were Caucasian with an age range of 20–25 years with an average height of 179 ± 3 cm. The average
weight of subjects was 77 ± 16 kg. Muscle was collected from each subject using a trephine biopsy
needle. Informed consent was obtained using guidelines approved by Sub-committee C of the Research
Committee of University of Stellenbosch (Ethics Number: N12/08/051,12 November 2012), following the
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principles of the Declaration of Helsinki. Participants completed a health history questionnaire and
had no muscle injury history. A needle biopsy was performed by a qualified doctor on the vastus
lateralis of the subjects to harvest the muscle samples. The muscle samples were dissected/minced into
1 mm3 pieces and transferred into a plate containing PHMPM. All cell culture growth surfaces were
pre-emptively coated with an ECL cell attachment matrix (Millipore, 08-110, Darmstadt, Germany).
The samples were maintained in a semi-conditioned media by removing half of the old media in each
well and replacing it with fresh media at regular intervals. The human primary myoblasts started to
migrate off the fibers approximately 10 days post transfer. Biopsies were removed from the wells at
14 days post transfer and the adherent cells were subjected to sub-culturing in the respective primary
human myoblast media.
4.4. Human Primary Myoblasts Characterisation
Isolated human primary myoblasts were characterized by evaluation of Pax7 and desmin
expression via flow cytometric analysis as described before. Cells were trypsinised and resuspended
in cold PBS at approximately 1 × 106 cells/mL. Cells were fixed and permeabilized in a 1:1
Methanol/Acetone solution for 10 min on ice. Washing was done using PBS and resuspension was
done in 1% (v/v) bovine serum albumin (BSA). Cells were incubated in the presence of mouse anti-Pax7
(1:200) and rabbit anti-desmin (1:100) primary antibodies for 30 min at room temperature. Cells were
washed, centrifuged and resuspended in 1% (v/v) BSA. Secondary antibodies (donkey anti-mouse
Alexa 488 (1:200), donkey anti-rabbit IgG PerCP (1:100)) were added for 30 min at room temperature.
Cells were centrifuged and resuspended in PBS and stored on ice until they were analyzed using the
BD FACSAria™ Cell Sorter (BD Biosciences, San Jose, CA 95133 USA). To determine the myogenic
differentiation potential of primary human myoblasts, cells were treated with differentiation media
(DMEM, 2% horse serum). To evaluate terminal differentiation, myogenin levels were determined.
Proliferation of primary human myoblasts was determined using trypan blue staining and cell counting.
4.5. Cell Cycle Analysis
Approximately 1 × 105 cells were trypsinised and resuspended in citrate buffer. The pH of the
buffer was adjusted to 7.60. Cells treated with different concentrations of IL-6 for different time periods
were then processed for flow cytometric analysis in accordance with standard protocols with the aid of
a DNA reagent kit (BD Biosciences CycleTestTM Plus, 340242, San Jose, CA, USA). Cells were fixed
with 40% methanol and then incubated with Propidium Iodide and this was used to stain DNA prior
to flow cytometry. Cell cycle analysis was done using flow cytometry (BD FACSAria™ Cell Sorter,
BD Biosciences, San Jose, CA 95133 USA). About 1 × 104 cells were analyzed and cell cycle fractions
were quantified with ModFitLT 3.0 (Verity Software).
4.6. Immunoblot Analysis
Immunoblotting was carried out as described in standard procedures. At the end of each
treatment, C2C12 and primary myoblast cells were washed with PBS and lysed in RIPA buffer. Protease
inhibitors were added to prevent protein degradation. The following were the protease inhibitors
used—leupeptin (1 µg/mL; for lysosomal proteases), pepstatin A (1 µg/mL; for aspartic proteases);
Aprotinin (1 µg/mL; for trypsin and chymotrypsin); phenylmethylsulfonyl fluoride (PMSF, 1 µM,
for serine and cysteine); sodium fluoride (NaF, 1µM, for acidic phosphatases) and sodium orthovanadata
(1 mM, for tyrosine and alkaline phosphatases). Protein concentration was determined using the BCA
assay. Proteins (10 µg) were then separated on 6%–10% sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) gels in the presence of B-mercaptoethanol. Transfer of proteins was
done using a polyvinylidene difluoride (PVDF) membrane (Pall Corporation, Port Washington, NY,
USA, #T010981). Membranes were blocked with 5% (w/v) non-fat milk powder dissolved in 1% (v/v)
Tris buffered saline (TBS)-Tween buffer. Incubation with primary antibodies was done overnight at
4 ◦C. All primary antibodies utilized in this study are shown in Table 1. The membranes were washed
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twice with 1% (v/v) TBS-Tween and incubated with specific horseradish peroxidase (HRP)-conjugated
secondary antibodies (BioRad, Hercules, CA, USA) for 1 h at room temperature with constant agitation.
Secondary antibodies used in the study are shown in Table 2. Membranes were then washed twice
with 1% (v/v) TBS-Tween buffer. Detection of proteins was done using Chemiluminescence substrate
(SuperSignal West Femto Chemiluminescent Substrate, Thermo Scientific, Waltham, MA, USA, 23227)
and images were taken using the ChemiDocTM MP Imaging System (Bio-Rad Laboratories, Hercules,
CA, USA). Densitometric analysis was performed using Image LabTM Software (Bio-Rad Laboratories,
Hercules, CA, USA). All experiments were performed at least twice.
Table 1. Primary antibodies utilized for western blotting and immunocytochemistry.
1◦Antibody Manufacturer Species Catalogue Number
MyoD Santa Cruz Mouse SC32758
Myogenin Santa Cruz Mouse SC12732
PCNA Santa Cruz Rabbit SC7907
pSTAT3 Cell Signaling Rabbit 9131
tSTAT3 Cell Signaling Rabbit 9132
pJAK1 Santa Cruz Goat SC16773
pJAK2 Santa Cruz Goat SC21870
SOCS3 Santa Cruz Rabbit SC9023
SOCS1 Santa Cruz Rabbit SC9021
IL-6Rα Santa Cruz Rabbit SC13947
β-actin Cell Signaling Rabbit 4967
Table 2. Secondary antibodies utilized for western blotting.
2◦Antibody Manufacturer Description
Anti-mouse Abcam Goat HRP conjugated
Anti-rabbit Santa Cruz Goat HRP conjugated
Anti-goat Abcam Sheep HRP conjugated
4.7. Immunocytochemistry Staining
Primary myoblasts and C2C12 cells were cultured on top of glass slides and treated with IL-6 as
described above. Cells were fixed with 4% (v/v) paraformaldehyde for 15 min at room temperature.
Slides were washed twice with PBS for 5 min. Cells were permeabilized with 0.50% (v/v) Triton
X-100 (BDH Laboratories, Poole, UK, 306324N) in PBS for 15 min at room temperature. To prevent
non-specific binding, cells were blocked using 20% (v/v) Donkey Serum (D9663) for 30 min at room
temperature. Incubation with primary antibodies, diluted in 20% Donkey serum, was done overnight
at 4 ◦C. Cells were then incubated with the appropriate secondary antibodies, diluted in donkey
serum, for 60 min in the dark at room temperature. All primary and secondary antibodies used in the
analyses are listed in Table 1 above and Table 3 below, respectively. Incubation with a nuclear stain
(Bis Benzimide H33422 trihydrochloride, Sigma-Aldrich, Aston Manor, South Africa #B2261) was done
for 15 min at room temperature. Slides were visualized by fluorescence (Olympus IX81 fitted with
CellR®software, Waltham, MA, USA) or confocal microscopy (Carl Zeiss Confocal LSM 780 Elyra S1
fitted with Zen software, Jena, Germany). A minimum of three different images were obtained per
each treatment condition.
Table 3. Secondary antibodies utilized for immunocytochemistry.
2◦Antibody Manufacturer Species Product Number
Alexa Fluor 488 Invitrogen Donkey Anti-mouse IgG A21202
Alex Fluor 546 Invitrogen Donkey Anti-goat IgG A11056
Alexa Fluor 594 Invitrogen Donkey Anti-rabbit A21207
Int. J. Mol. Sci. 2019, 20, 5273 24 of 30
4.8. RNA Preparation and RT-qPCR
Total RNA was isolated from cells using Trizol reagent (BioRad, California, USA) based on the
procedure of Chomczynski and Sacchi [112]. The quality and quantity of the RNA was assessed
using spectrophotometry and agarose gel electrophoresis. Total RNA from each sample was reverse
transcribed using the First Strand cDNA Synthesis kit (Roche, Belmont, CA, USA, 04896866001)
according to the manufacturers’ instructions. Random hexamers were added to the DNase treated RNA
and was incubated in the thermal cycler for 10 min at 65 ◦C. Quantitative PCR was performed to detect
IL-6R mRNA and monitored using the StepOnePlus™ System (Life Technologies, Carlsbad, CA, USA).
cDNA samples from triplicate samples were analyzed using primers as shown in Table 4. Conditions
for thermocycling were: 2 min at 50 ◦C, initial denaturation for 10 min at 95 ◦C, followed by 40 cycles of
15 s at 95 ◦C and 1 min at 60 ◦C and 72 ◦C for 20 s. The CT value represents the target threshold which
is the number of cycles necessary for the fluorescent signal generated to rise above the background
levels. The CT is inversely proportional to the number of mRNA transcripts, so a lower CT would
indicate higher mRNA transcripts. Relative gene expression was then computed for each sample in
comparison with each corresponding control by using the ddCT method. The amount of target mRNA
was then finally calculated by the equation: amount of target = 2−ddCT [113]. The beta-2-microglobulin
(B2M) gene was used as the housekeeping gene.
Table 4. Primers utilized for quantitative polymerase chain reaction (qPCR).
Primer Manufacturer Primer Code
IL-6R Applied Biosystems Hs1075666_m1
Housekeeping (B2M) Applied Biosystems Hs00984230_m1
4.9. Statistical Analysis
Statistical analysis was done using GraphPad Prism version 5. Data were expressed as
means ± Standard error of the mean (S.E.M). ANOVA and the Bonferroni post hoc test were used to
ascertain the statistically significant differences between controls and treated samples. Data: n = 3
observations in each experiment was 3. Each observation was done on myoblasts obtained from other
donors. Statistical significance was accepted when * p < 0.05; ** p < 0.01; *** p < 0.001.
5. Conclusions
This study demonstrated that IL-6 play key roles in myoblasts proliferation and differentiation,
with the myokine displaying both concentration and time-dependent effects on myoblasts fate.
IL-6 activates different components of the JAK-STAT signaling pathway to influence the fate of
myoblasts. Overall, our study has deepened our understanding of the role of IL-6 in myoblasts
proliferation and differentiation. Furthermore, we have revealed that the IL-6/JAK/STAT/SOCS
pathway is a promising therapeutic target in muscle wasting pathological conditions.
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Abbreviations
CD34 Cluster of Differentiation 34
FBS Fetal Bovine Serum
HGF Hepatocyte Growth Factor
IL-6 Interleukin 6
JAK Janus kinase
LIF Leukemia Inhibitory Factor
MEF Myocyte Enhancer-binding Factor
MRFs Myogenic Regulatory Factors
PCNA Proliferating Cell Nuclear Antigen
PHM Primary Human Myoblast
SOCS Suppressor of Cytokine Signaling
STAT Signal Transducer and Activator of Transcription
TGF-β Transforming Growth Factor-β
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